vs

Side-by-side financial comparison of Alignment Healthcare, Inc. (ALHC) and Edwards Lifesciences (EW). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.6× Alignment Healthcare, Inc.). Edwards Lifesciences runs the higher net margin — 23.1% vs -1.1%, a 24.2% gap on every dollar of revenue. On growth, Alignment Healthcare, Inc. posted the faster year-over-year revenue change (44.4% vs 16.7%). Over the past eight quarters, Alignment Healthcare, Inc.'s revenue compounded faster (26.9% CAGR vs 9.7%).

Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

ALHC vs EW — Head-to-Head

Bigger by revenue
EW
EW
1.6× larger
EW
$1.6B
$1.0B
ALHC
Growing faster (revenue YoY)
ALHC
ALHC
+27.7% gap
ALHC
44.4%
16.7%
EW
Higher net margin
EW
EW
24.2% more per $
EW
23.1%
-1.1%
ALHC
Faster 2-yr revenue CAGR
ALHC
ALHC
Annualised
ALHC
26.9%
9.7%
EW

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ALHC
ALHC
EW
EW
Revenue
$1.0B
$1.6B
Net Profit
$-11.0M
$380.7M
Gross Margin
78.0%
Operating Margin
-1.0%
1.8%
Net Margin
-1.1%
23.1%
Revenue YoY
44.4%
16.7%
Net Profit YoY
64.6%
6.8%
EPS (diluted)
$-0.04
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALHC
ALHC
EW
EW
Q1 26
$1.6B
Q4 25
$1.0B
$1.6B
Q3 25
$993.7M
$1.6B
Q2 25
$1.0B
$1.5B
Q1 25
$926.9M
$1.4B
Q4 24
$701.2M
$1.4B
Q3 24
$692.4M
$1.4B
Q2 24
$681.3M
$1.4B
Net Profit
ALHC
ALHC
EW
EW
Q1 26
$380.7M
Q4 25
$-11.0M
$91.2M
Q3 25
$3.7M
$291.1M
Q2 25
$15.7M
$333.2M
Q1 25
$-9.1M
$358.0M
Q4 24
$-31.1M
$385.6M
Q3 24
$-26.4M
$3.1B
Q2 24
$-24.0M
$366.3M
Gross Margin
ALHC
ALHC
EW
EW
Q1 26
78.0%
Q4 25
78.1%
Q3 25
77.8%
Q2 25
77.5%
Q1 25
78.7%
Q4 24
78.9%
Q3 24
80.6%
Q2 24
79.9%
Operating Margin
ALHC
ALHC
EW
EW
Q1 26
1.8%
Q4 25
-1.0%
9.6%
Q3 25
0.8%
19.8%
Q2 25
2.2%
26.8%
Q1 25
-0.6%
27.9%
Q4 24
-3.2%
22.6%
Q3 24
-2.8%
25.9%
Q2 24
-2.7%
26.8%
Net Margin
ALHC
ALHC
EW
EW
Q1 26
23.1%
Q4 25
-1.1%
5.8%
Q3 25
0.4%
18.7%
Q2 25
1.5%
21.7%
Q1 25
-1.0%
25.3%
Q4 24
-4.4%
27.8%
Q3 24
-3.8%
226.7%
Q2 24
-3.5%
26.7%
EPS (diluted)
ALHC
ALHC
EW
EW
Q1 26
$0.66
Q4 25
$-0.04
$0.16
Q3 25
$0.02
$0.50
Q2 25
$0.07
$0.56
Q1 25
$-0.05
$0.61
Q4 24
$-0.15
$0.65
Q3 24
$-0.14
$5.13
Q2 24
$-0.13
$0.61

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALHC
ALHC
EW
EW
Cash + ST InvestmentsLiquidity on hand
$604.2M
Total DebtLower is stronger
$323.2M
Stockholders' EquityBook value
$179.3M
Total Assets
$1.1B
Debt / EquityLower = less leverage
1.80×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALHC
ALHC
EW
EW
Q1 26
Q4 25
$604.2M
$4.2B
Q3 25
$644.1M
$3.8B
Q2 25
$503.8M
$4.1B
Q1 25
$479.5M
$3.9B
Q4 24
$470.6M
$4.0B
Q3 24
$381.0M
$4.4B
Q2 24
$363.7M
$2.0B
Total Debt
ALHC
ALHC
EW
EW
Q1 26
Q4 25
$323.2M
Q3 25
$322.7M
Q2 25
$322.3M
Q1 25
$321.9M
Q4 24
$321.4M
Q3 24
$212.0M
Q2 24
$211.7M
Stockholders' Equity
ALHC
ALHC
EW
EW
Q1 26
Q4 25
$179.3M
$10.3B
Q3 25
$161.9M
$10.2B
Q2 25
$141.0M
$10.5B
Q1 25
$108.1M
$10.1B
Q4 24
$99.9M
$10.0B
Q3 24
$114.5M
$9.5B
Q2 24
$123.7M
$7.4B
Total Assets
ALHC
ALHC
EW
EW
Q1 26
Q4 25
$1.1B
$13.7B
Q3 25
$1.1B
$13.3B
Q2 25
$1.0B
$13.5B
Q1 25
$895.6M
$13.0B
Q4 24
$782.1M
$13.1B
Q3 24
$692.3M
$13.0B
Q2 24
$716.3M
$10.1B
Debt / Equity
ALHC
ALHC
EW
EW
Q1 26
Q4 25
1.80×
Q3 25
1.99×
Q2 25
2.29×
Q1 25
2.98×
Q4 24
3.22×
Q3 24
1.85×
Q2 24
1.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALHC
ALHC
EW
EW
Operating Cash FlowLast quarter
$-50.4M
Free Cash FlowOCF − Capex
$-55.4M
FCF MarginFCF / Revenue
-5.5%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$113.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALHC
ALHC
EW
EW
Q1 26
Q4 25
$-50.4M
$450.9M
Q3 25
$144.6M
$573.7M
Q2 25
$29.1M
$290.2M
Q1 25
$16.6M
$280.4M
Q4 24
$-8.7M
$-127.5M
Q3 24
$26.2M
$351.8M
Q2 24
$23.5M
$371.5M
Free Cash Flow
ALHC
ALHC
EW
EW
Q1 26
Q4 25
$-55.4M
$353.5M
Q3 25
$139.1M
$516.2M
Q2 25
$21.1M
$240.9M
Q1 25
$8.4M
$224.4M
Q4 24
$-18.0M
$-177.3M
Q3 24
$16.9M
$299.9M
Q2 24
$11.8M
$286.1M
FCF Margin
ALHC
ALHC
EW
EW
Q1 26
Q4 25
-5.5%
22.5%
Q3 25
14.0%
33.2%
Q2 25
2.1%
15.7%
Q1 25
0.9%
15.9%
Q4 24
-2.6%
-12.8%
Q3 24
2.4%
22.1%
Q2 24
1.7%
20.9%
Capex Intensity
ALHC
ALHC
EW
EW
Q1 26
Q4 25
0.5%
6.2%
Q3 25
0.6%
3.7%
Q2 25
0.8%
3.2%
Q1 25
0.9%
4.0%
Q4 24
1.3%
3.6%
Q3 24
1.3%
3.8%
Q2 24
1.7%
6.2%
Cash Conversion
ALHC
ALHC
EW
EW
Q1 26
Q4 25
4.94×
Q3 25
38.77×
1.97×
Q2 25
1.86×
0.87×
Q1 25
0.78×
Q4 24
-0.33×
Q3 24
0.11×
Q2 24
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons